SCHEMBL14814637

SCHEMBL14814637

O=C(COc1ccc(OC(F)(F)F)cc1)N1CCN2C[C@H](Oc3cnc(C4CC4)cn3)C[C@H]2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 2/20 0.45
▸ ALDH1A1 P00352 4/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ ORAI1 Q96D31 1/20 0.39
▸ MAPT P10636 3/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ GAA P10253 2/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ ABL1 P00519 1/20 0.36
▸ SCN9A Q15858 4/20 0.36
▸ SCN10A Q9Y5Y9 1/20 0.36
▸ MAPK7 Q13164 1/20 0.35
▸ MCHR1 Q99705 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14814755 0.91 ALDH1A1 (0.47) HRH3ALDH1A1KDM4EORAI1MAPT
SCHEMBL14814775 0.85 MAPT (0.46) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL14815365 0.83 MGLL (0.41) SCN9ASCN10AMAPK7
SCHEMBL14814586 0.82 MAPT (0.46) HRH3KDM4EMAPTKMT2ARAB9A
SCHEMBL14815105 0.82 HSD11B1 (0.44) HRH3ALDH1A1KDM4EMEN1KMT2A
SCHEMBL14814957 0.80 LIPE (0.45) HRH3SCN9ASCN10A
SCHEMBL14815054 0.79 MGLL (0.39) HRH3SCN9ASCN10AMAPK7KCNH2
SCHEMBL14815590 0.79 MEN1 (0.45) MEN1KMT2ASMN1; SMN2SCN9AHTT
SCHEMBL14814708 0.79 SMN1; SMN2 (0.42) HRH3ALDH1A1KDM4EMAPTMEN1
SCHEMBL14815350 0.79 HRH3 (0.38) HRH3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669255-B2 Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers ABBVIE INC. (US) 2014-03-11 — — US disclosed
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-04-04 — — US disclosed
WO-2013049164-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS CACNA1C, CACNA1E, CACNA1D HRH3 1244/4885ALDH1A1 1283/4885KDM4E 3058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback